Year End Update

Venn Life Sciences Holdings Plc
(“Venn Life Sciences” or the “Company”)

Year End Update

3 March 2017

Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations, today provides the following update.

2016 represented another year of strong growth for Venn with sales in excess of €18m (2015 €11m). The business finished 2016 with a strong cash position of €3m (€1.75m 30 June 2016). The strong momentum enjoyed by the business in 2016 has continued into 2017 todate, with new business contracts signed to the value €5.7m in the first two months of the year.

Enquiries:

Venn Life Sciences Holdings Plc   www.vennlifesciences.com
Tony Richardson, Chief Executive Officer   Tel: +353 1 549 9341

Davy (Nominated Adviser, ESM Adviser and Joint Broker)
Fergal Meegan / Matthew de Vere White (Corporate Finance) – Tel: +353 1 679 6363

Hybridan LLP (Joint-Broker)
Claire Louise Noyce   Tel: +44 (0) 20 3764 2341

Walbrook PR Ltd
Tel: +44 (0) 20 7933 8787 or venn@walbrookpr.com
Paul McManus Mob: +44 (0) 7980 541 893 / Lianne Cawthorne: Mob: +44 (0) 7584 391 303

About Venn Life Sciences Limited: Venn Life Sciences is a Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation – Venn specialises in rapid deployment and management of multisite projects.